[Podcast] The Straight Dope on Hospital and Payer Transparency Rules
Three transparency rules have come out of CMS in the past months. The first was announced last year, and it [...]
Beyond COVID-19: Life sciences reimagined
Every biopharma function has had to evaluate and adapt its roles and responsibilities almost overnight. So, how do we navigate [...]
Digital Therapeutics and Payers
The DTx market has grown more than 50% over the last 3 years, with many new technologies entering the market. [...]
The Syneos Health Podcast: Payer Power, Part 2
This episode of the Payer Power Podcast explores the impact of strategies payers were starting to bring to the marketplace [...]
Women in HEOR: Adapting to the New Normal
The COVID-19 pandemic has changed the lives of professionals worldwide, with working from home or remotely being the “new normal.” [...]
Surprise Federal Drug Rule Requires Price Transparency from Insurers
Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public [...]
ICER Recommendations Can Be Influenced With the Right Evidence
Based on previous ICER reports, when a pharma product goes through an ICER assessment, there is an extremely high chance [...]
A Patient-centered Look at Specialty Rx Abandonment
Prescription abandonment, when the patient does not fill or pick up a prescription, exacts a heavy financial and human toll [...]
Syneos Health Podcast: Payer Power
Keith Kelly, Senior Managing Director, Value, Access and HEOR at Syneos Health, asserts that the entirety of the US healthcare [...]
The Benefits of Continuous AI Reprioritization in Systematic Reviews
Systematic reviews are a time-consuming and resource-intensive process; even small projects can take several months to complete. , Today there [...]
London School of Hygiene and Tropical Medicine and iDSI Launch COVID-related Platform for HEOR Professionals
The iDSI (International Decision Support Initiative) and London School of Hygiene and Tropical Medicine (LSHTM) just announced the launch of [...]
Rob Barker Appointed CEO of OPEN Health Group
Rob Barker will be succeeding David Rowley as Chief Executive Officer of leading multi-disciplinary health communications and market access group [...]
Minimizing Risk & Accelerating Timelines in Oncology Trials
Cancer has an etiology that involves a wide range of genetic interactions and dysfunction across multiple systems. These characteristics make [...]
Free Medical Science Liaison (MSL) and MSL Manager Mentor Program
The MSL Mentor Program is a unique program, provided free of charge, that exemplifies The Medical Science Liaison Society's mission [...]
[Webinar] Conducting Qualification and Validation in the Era of Covid-19
In a process known as qualification and validation, regulatory agencies such as FDA, EMA and WHO, require that the pharmaceutical, [...]
[Whitepaper] How Can Real-World Evidence Support Adoption of New Technology?
The application of real-world evidence (RWE) as a healthcare decision-making tool has the potential to significantly improve patient outcomes, patient [...]
Bayesian Methods for Multiple Cohort Expansion (MuCE) designs
Cohort expansion trials where multiple dose(s) and multiple indication(s) need to be tested in parallel can present complex problems for [...]
Fabio Pammolli Summarizes Research on Pharma R&D
According to Pammoli, screening has improved (attrition rates decreasing in all phases of clinicaltrials) and focus has shifted to oncology, [...]
EVERSANA Implements Holistic Commercialization Strategies
EVERSANA, the leading provider of global services to the life sciences industry, is developing an integrated and independent commercial services [...]
ICER Finds That Supervised Injection Facilities Save Lives and Money
ICER has concluded that there is sufficient evidence demonstrating that supervised injection facilities (SIFs) prevent overdose deaths and reduce overall [...]
The Emergence of ICER in American Pharma
Joe Biden recently suggested that Medicare drug-price negotiations should follow the German model where negotiations between government and drugmakers are informed [...]
Michael L. Ryan of Bristol Myers Squibb Elected Board Chair of National Pharmaceutical Council
Today the National Pharmaceutical Council (NPC) announced that Michael L. Ryan, PharmD, Senior Vice President, Worldwide Value, Access, Pricing and [...]
Advanced Design Framework with Yannis Jemiai
The clinical trial design process has been irrevocably altered by cloud-based computing. Until recently, it would take a statistician a [...]
[Webinar] How Health Care Innovation Affects Life Expectancy and Patient Well-Being
The American Journal of Managed Care® recently hosted a webinar entitled "Bang for the Buck: How Health Care Innovation Affects [...]
ICER Releases Draft Evidence Report on Treatments for High Cholesterol
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report evaluating the comparative clinical effectiveness and [...]